SEC Filing Summary: Form 6-K
Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of July 2025. The filing, dated July 23, 2025, serves to incorporate by reference a press release (Exhibit 99.1) issued on the same date. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Form 20-F.
Financial Metrics
The provided filing text contains no financial data. It does not report revenue, profit, cash flow, margins, debt, or liquidity figures. The document is a procedural filing to distribute a press release rather than a financial statement.
Material Changes
The filing text does not disclose specific material changes in financial position or operations. It solely references the issuance of a press release on July 23, 2025, the content of which is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or risk factors. It notes that quotes from Jérôme Contamine and Henry Gosebruch in the attached press release are not incorporated by reference into the company's Registration Statements on Form S-8.
Key Facts for Investor Verification
- Company Identity: Verify that the filing pertains to Galapagos NV, not Lakefront Biotherapeutics NV.
- Press Release Content: The substantive information is located in Exhibit 99.1 (the press release), which is not included in the provided text.
- Exclusions: Note that specific executive quotes in the press release are excluded from incorporation into Form S-8 registration statements.
- Financial Data: No financial metrics are available in this specific filing document.